Characteristics of JMML patients with low and high LIN28B expression
| . | Total patients, n = 82 . | LIN28B-low patients, n = 40 . | LIN28B-high patients, n = 42 . | P . |
|---|---|---|---|---|
| Median age at diagnosis, y (range) | 2.0 (0.1-17.9) | 1.3 (0.1-17.9) | 2.6 (0.2-6.4) | <.01 |
| Median platelets, 109/L (range) | 57 (5-530) | 71 (5-530) | 40 (8-197) | .01 |
| Median blasts in BM, % (range) | 5 (0-37) | 6 (0-20) | 5 (0-37) | NS |
| Median HbF, % (range)* | 14 (1-70) | 4 (1-67) | 34 (1-70) | <.01 |
| HbF >97th percentile for age, n (%)† | 55 (78) | 21 (60) | 34 (94) | <.01 |
| Male/female, n (%) | 58/24 (71/29) | 30/10 (75/25) | 28/14 (67/33) | NS |
| Mutational analysis, n (%) | .05 | |||
| PTPN11 | 36 (44) | 11 (28) | 25 (60) | |
| KRAS | 15 (18) | 10 (25) | 5 (12) | |
| NRAS | 15 (18) | 8 (20) | 7 (17) | |
| NF1 | 5 (6) | 3 (8) | 2 (5) | |
| Quadruple negative | 11 (13) | 8 (20) | 3 (7) | |
| Karyotype, n (%) | <.01 | |||
| Monosomy 7 +add‡ | 17 (21) | 14 (35) | 3 (7) | |
| Normal | 54 (66) | 25 (63) | 29 (69) | |
| Other | 8 (10) | 1 (3) | 7 (17) | |
| No result | 3 (4) | 0 (0) | 3 (7) | |
| Alive at last follow-up, n (%) | 40 (49) | 23 (58) | 17 (41) | NS |
| Received HSCT, n (%) | 77 (94) | 37 (93) | 40 (95) | NS |
| Alive after HSCT, n (%) | 38 (49) | 21 (57) | 17 (43) | NS |
| Events after HSCT, n (%) | ||||
| TRM | 19 (25) | 7 (19) | 12 (30) | |
| Relapse | 23 (30) | 10 (27) | 13 (33) | |
| Primary graft failure alive | 2 (3) | 0 (0) | 2 (5) | |
| No event | 33 (43) | 20 (54) | 13 (33) | NS |
| . | Total patients, n = 82 . | LIN28B-low patients, n = 40 . | LIN28B-high patients, n = 42 . | P . |
|---|---|---|---|---|
| Median age at diagnosis, y (range) | 2.0 (0.1-17.9) | 1.3 (0.1-17.9) | 2.6 (0.2-6.4) | <.01 |
| Median platelets, 109/L (range) | 57 (5-530) | 71 (5-530) | 40 (8-197) | .01 |
| Median blasts in BM, % (range) | 5 (0-37) | 6 (0-20) | 5 (0-37) | NS |
| Median HbF, % (range)* | 14 (1-70) | 4 (1-67) | 34 (1-70) | <.01 |
| HbF >97th percentile for age, n (%)† | 55 (78) | 21 (60) | 34 (94) | <.01 |
| Male/female, n (%) | 58/24 (71/29) | 30/10 (75/25) | 28/14 (67/33) | NS |
| Mutational analysis, n (%) | .05 | |||
| PTPN11 | 36 (44) | 11 (28) | 25 (60) | |
| KRAS | 15 (18) | 10 (25) | 5 (12) | |
| NRAS | 15 (18) | 8 (20) | 7 (17) | |
| NF1 | 5 (6) | 3 (8) | 2 (5) | |
| Quadruple negative | 11 (13) | 8 (20) | 3 (7) | |
| Karyotype, n (%) | <.01 | |||
| Monosomy 7 +add‡ | 17 (21) | 14 (35) | 3 (7) | |
| Normal | 54 (66) | 25 (63) | 29 (69) | |
| Other | 8 (10) | 1 (3) | 7 (17) | |
| No result | 3 (4) | 0 (0) | 3 (7) | |
| Alive at last follow-up, n (%) | 40 (49) | 23 (58) | 17 (41) | NS |
| Received HSCT, n (%) | 77 (94) | 37 (93) | 40 (95) | NS |
| Alive after HSCT, n (%) | 38 (49) | 21 (57) | 17 (43) | NS |
| Events after HSCT, n (%) | ||||
| TRM | 19 (25) | 7 (19) | 12 (30) | |
| Relapse | 23 (30) | 10 (27) | 13 (33) | |
| Primary graft failure alive | 2 (3) | 0 (0) | 2 (5) | |
| No event | 33 (43) | 20 (54) | 13 (33) | NS |